WO2001024786A1 - Principes actifs destines au soin ou a la prevention de diabetes - Google Patents
Principes actifs destines au soin ou a la prevention de diabetes Download PDFInfo
- Publication number
- WO2001024786A1 WO2001024786A1 PCT/JP2000/002992 JP0002992W WO0124786A1 WO 2001024786 A1 WO2001024786 A1 WO 2001024786A1 JP 0002992 W JP0002992 W JP 0002992W WO 0124786 A1 WO0124786 A1 WO 0124786A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lower alkyl
- optionally substituted
- substituted
- compound
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
Definitions
- the present invention relates to a medicament, particularly a preventive or therapeutic drug for diabetes.
- Diabetes is generally categorized as insulin-dependent (type I, IDDM) with a decrease in insulin-producing cells and insulin-independent (type II. NIDDM) caused by decreased insulin sensitivity. .
- type II diabetes insulin-independent diabetes
- the blood insulin level is high, but the sensitivity of somatic cells to insulin is reduced. Uptake is blocked.
- thiazolidine derivatives eg, troglitazone, pioglitazone, rosiglitazone
- references disclosing arylsulfonamide derivatives include, for example, WO96 / 3310 (use: insecticide), SU159696 (use: insecticide, growth promoter), JP (A) 0 7/2 0 68 15 (use: insecticide, antibacterial agent) and the like are known, but the literature does not describe any preventive or therapeutic drug for diabetes. Thus, there is a need for the development of new preventive or therapeutic agents for type I or type I diabetes. Disclosure of the invention
- the present inventors have conducted intensive studies and have found that certain amide derivatives, sulfonamide derivatives, or other compounds have an effect of lowering blood glucose concentration.
- the present invention has been found to be useful as a drug for preventing or treating diabetes, and has completed the present invention described below.
- A is an optionally substituted aryl or an optionally substituted heteroaryl
- B is lower alkyl, optionally substituted aryl, optionally substituted aryl lower alkyl, optionally substituted aryl lower alkenyl, optionally substituted heteroaryl, optionally substituted A good heteroaryl lower alkyl, or an optionally substituted heteroaryl lower alkenyl;
- X 1 is one 0—, one S— or one NR a — (R a is hydrogen or lower alkyl);
- X 2 is one NR b CO—, — CONR b— , one NR b CONR b— , one S 0 2 -, One NR b S 0 2 -,-D-, one D-0-, one D-CO-,-D-S 02-D-NR b CO-, or-D-NR b S 0 2-
- D is a divalent heterocyclic group; R b is hydrogen or lower alkyl which may be substituted);
- n is an integer from 0 to 3;
- n an integer of 2 to 5.
- a prodrug thereof, a pharmaceutically acceptable salt thereof, or a solvate thereof for preventing or treating diabetes.
- A is phenyl which may be substituted, naphthyl which may be substituted, pyridyl which may be substituted, quinolyl which may be substituted, isoquinolyl which may be substituted;
- the preventive or therapeutic agent for diabetes according to the above (1) which is an optionally substituted furyl, an optionally substituted phenyl, an optionally substituted benzofuryl, or an optionally substituted benzozonitrile.
- (3) The agent for preventing or treating diabetes according to the above (2), wherein A is phenyl which may be substituted.
- A is one or more groups selected from the group consisting of halogen, lower alkyl, lower alkoxy and halogenated lower alkyl, and phenyl substituted by substituted phenyloxy. Prophylactic or therapeutic drugs.
- (10) B is lower alkyl, phenyl which may be substituted, benzyl which may be substituted, 2-phenylvinyl which may be substituted, pyridyl which may be substituted, and optionally substituted Good 2-pyridylvinyl, optionally substituted furyl, optionally substituted 2-furylvinyl, optionally substituted phenyl, optionally substituted 2-phenylvinyl, or substituted
- the preventive or therapeutic drug for diabetes according to the above (1), which is thiomorpholinyl.
- the substituent is halogen, amino, carboxyl, hydroxy, cyano, lower alkyl, optionally substituted lower alkoxy, lower alkoxycarbonyl, halogen
- the preventive or therapeutic agent for diabetes according to the above (1) which is selected from the group consisting of lower alkyl halides, aryloxy, and heteroaryloxy.
- X 1 is 0, the (1) diabetes prophylactic or therapeutic agent according.
- A is phenyl which may be substituted;
- B is lower alkyl, phenyl which may be substituted, benzyl which may be substituted, 2-phenylvinyl which may be substituted, substituted Optionally substituted pyridyl, optionally substituted 2-pyridylvinyl, optionally substituted furyl, optionally substituted 2-furylvinyl, optionally substituted phenyl, optionally substituted 2-thienyl vinyl or may thiomorpholinyl optionally substituted,;
- X 1 is 0;
- D is piperidin 1,4—diyl or piperazine 1,4 Jiiru
- a 1 is the formula: , J
- each R 1 R 2 and R 3 independently represent hydrogen, halogen, lower alkyl, lower alkoxy, halogenated lower alkyl, or substituted phenyloxy).
- B 1 is lower alkyl or a formula:
- R 4 and R 5 are each independently hydrogen, halogen, amino, carboxyl, hydroxy, cyano, lower alkyl, optionally substituted lower alkoxy, lower alkoxycarbonyl, halogenated lower alkyl, ⁇ Represents a group represented by phenyl or heteroaryloxy.
- X 1 is 100—, 1 S— or 1 NR a — ( Ra is hydrogen or lower alkyl);
- X 2 is 1 NR b CO—, — CONR b— , 1 NR b C 0NR b— , 1 S 0 2- , one NR b S 0 or formula:
- R b is each independently hydrogen or lower alkyl which may be substituted
- n is an integer from 0 to 3;
- n an integer of 2 to 5.
- a 1 is a group represented by (a), R 1 is hydrogen, R 2 and R 3 are carbon atoms; B 1 is a group represented by (o), R 4 is amino or methyl, and R 5 is hydrogen; X 1 is 0; X 2 is NR b S 0 2 ; m is 0; and n is 2; and 2) A is (a) group, R 1 is hydrogen, R 2 and R 3 are hydrogen, halogen X 1 is 0; X 2 is a group represented by (X-1); B 1 is lower alkyl or phenyl; m is 0; and n is 3 In case of, exclude. )
- a 1 has the formula:
- a 1 is (al); R 1 is hydrogen; R 2 is halogen, lower alkyl, lower alkoxy, halogenated lower alkyl, or substituted phenyloxy; R 3 is hydrogen, halogen, lower alkyl, lower
- B 1 is a group of (0), (ol) or (02); R 4 is hydrogen, R 5 is hydrogen, nitrogen, amino, carboxyl, hydroxy, hydroxy, cyano, lower alkyl, substituted (18)
- X 2 is —NH CO—, one NH CONH—, one NH S ⁇ 2 —, or formula:
- a 1 is (al); R 1 is hydrogen; R 2 is halogen, lower alkyl, lower alkoxy, halogenated lower alkyl, or substituted phenyloxy; R 3 is hydrogen, halogen, lower alkyl, lower alkoxy Or a lower alkyl halide; a group wherein B 1 is (0), (ol) or (o2); R 4 is hydrogen, R 5 is hydrogen, halogen, amino, carboxyl, hydroxy, cyano, lower alkyl, substituted Lower alkoxy, lower alkoxycarbonyl, lower alkyl halide, aryloxy, or heteroaryloxy; X 1 is 0; X 2 is —NHC 0—, —NHCONH—, and one NHSO. —, Or expression:
- An agent for preventing or treating diabetes comprising the compound according to any one of (17) to (27).
- a method for preventing or treating diabetes comprising administering the compound according to any one of (1) to (27).
- Lower alkyl includes straight or branched C 1 -C 6 alkyl, such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n— Examples include pentyl, i-pentyl, neo-pentyl, tert-pentyl, n-hexyl and the like. Preferably it is C1-C4 alkyl, especially methyl, n-butyl.
- Lower alkenyl includes linear or branched C 2 -C 6 alkenyl, and examples include vinyl, aryl, i-propenyl, 2-butenyl, 3-pentenyl, 2-hexenyl and the like. Preferably, it is C 2 -C 4 alkenyl, especially vinyl.
- the lower alkoxy includes the oxy bonded to the lower alkyl, and examples thereof include methoxy, ethoxy, i-propoxy, tert-butoxy, pentyloxy, and hexyloxy. Preferred is methoxy.
- Halogen means F, Cl, Br, I. Preferably, it is F or C1.
- Aryl means a monocyclic or condensable aromatic hydrocarbon group and includes, for example, phenyl, sodium naphthyl, naphthyl, anthryl, indenyl, phenanthryl and the like. Preferred are phenyl, para-naphthyl and / 5-naphthyl, and particularly preferred is phenyl.
- Heteroaryl means an aromatic monocyclic or polycyclic group containing the same or different heteroatoms selected from 0, S and N.
- the monocyclic group includes a 5- to 6-membered ring group containing 1 to 4 hetero atoms
- the aromatic ring group include pyridyl, furyl, chenyl, tetrazolyl, pyrrolyl, pyrazolyl, imidazolyl, Examples thereof include oxazolyl, thiazolyl, thiadiazolyl, oxazinyl, triazinyl and the like, preferably pyridyl (eg, 2-pyridyl, 3-pyridyl, 4-pyridyl), frill (eg, 2-furyl, 3-furyl). , Chenil (eg, 2-Chenyl, 3-Chenyl).
- the polycyclic group includes a bicyclic or tricyclic heterocyclic group containing 1 to 5 heteroatoms, and is preferably an 8- to 14-membered ring, for example, quinolyl, isoquinolyl, indolyl, Benzomidazolyl, indazolyl, indolizinyl, benzofuryl, benzothienyl, ataridinyl, phenanthridinyl and the like are exemplified, and more preferably quinolylyl (eg, 4-quinolyl, 5-quinolyl), isoquinolyl (eg, 41-quinolyl) Isoquinolyl, 5-isoquinolyl), benzofuryl (eg, 5-benzo [b] furyl), and benzochenil (eg, 5-benzo [b] chenyl).
- quinolyl eg, 4-quinolyl, 5-quinolyl
- isoquinolyl eg, 41-quinolyl
- substituents on the ring group represented by A are RR 2 , R 3 and the like of the preceding group, and preferred substituents on the ring group represented by B are R 4 and the like of the preceding group.
- A is preferably phenyl which may be substituted (eg, phenyl, 2,3-dichlorophenyl, 2,4-difluorophenyl, phenyl substituted with methyl and methyl, dimethylphenyl), and substituted.
- May be naphthyl eg, phenyl- or /?-Naphthyl, 4-chloro-one-naphthyl
- optionally substituted pyridyl eg, 4-monopyridyl, 6-chloro-2-hydroxy-4-pyridyl
- optionally substituted quinolyl eg, 5-quinolyl, 6-chloro-18-hydroxy-5-quinolyl
- optionally substituted isoquinolyl eg, 4-isoquinolyl, 6-Chloro-4 monoisoquinolyl
- optionally substituted furyl eg, 2—furyl, 4 1-chloro-2- (furyl)
- optionally substituted chenyl eg, 2—thio) Phenyl, 4-chloro-2-phenyl
- optionally substituted benzofuryl eg, 5-benzo [b] furyl, 3-chloro-5-benzo [b] furyl
- Ri each group der of the A 1, particularly preferably 3 A is 1, especially off substituted by two halogen Eniru, phenyl substituted by halogen and lower alkyl, the two By phenyl substituted by lower alkyl, phenyl substituted by substituted phenyloxy, or one or more groups selected from the group consisting of halogen, lower alkyl, lower alkoxy and halogenated lower alkyl; and substituted phenyloxy. It is a substituted phenyl. From the viewpoint of oral absorption, A is particularly preferably phenyl substituted by substituted phenyloxy.
- B is preferably n-butyl, phenyl which may be substituted, benzyl which may be substituted, 2-phenylvinyl which may be substituted, or pyridyl which may be substituted (eg, 3 — Pyridyl, 4-pyridyl), optionally substituted 2-pyridylvinyl (eg, 2- (4-pyridyl) vinyl), optionally substituted furyl (eg, 2-furyl, 3-furyl) ), Optionally substituted 2-furylvinyl (eg, 2- (3-furyl) vinyl), optionally-substituted chenyl (eg, 2-phenyl, 3-phenyl), or substituted May be 2-vinyl (eg: 2- (3-phenyl) vinyl).
- these substituents are nodogen, amino, carboxyl, lower alkyl (eg, methyl, t-butyl), lower alkoxy (eg, methoxy), 4-pyridyloxy, phenoxy, etc., and the substitution position is preferably It is para rank.
- Particularly preferred are phenyl which may be substituted, 2-phenylvinyl which may be substituted, and pyridyl.
- each group of said B 1 is encompassed.
- X 1 is preferably 0 or S, particularly preferably 0.
- substituent in the “optionally substituted lower alkyl” in R b include amino, substituted amino (substituent: lower alkyl such as methyl and ethyl), hydroxy, carboxyl, and lower alkoxycarbonyl (eg, methoxycarbonyl). , Ethoxycarbonyl, etc.), optionally substituted aryl (eg, p-carboxyphenyl, P-methoxycarbonylphenyl, etc.), and optionally substituted or condensed heterocycle (eg, Phthalimide, etc.) and the like, but carboxy is preferred.
- Rb is hydrogen, methyl, ethyl, propyl, aminomethyl, aminoethyl, methylaminopropyl, hydroxypropyl, carboxyethyl, methoxycarbonylethyl, p-carboxybenzyl, p-methoxybenzyl, Phthalimide propyl and the like are exemplified, but carboxymethyl and the like are preferable.
- Rb is hydrogen, methyl, ethyl, propyl, aminomethyl, aminoethyl, methylaminopropyl, hydroxypropyl, carboxyethyl, methoxycarbonylethyl, p-carboxybenzyl, p-methoxybenzyl, Phthalimide propyl and the like are exemplified, but carboxymethyl and the like are preferable.
- R b When a plurality of R b are present in one group, they may be the same or different.
- m is preferably 0.
- n is preferably 3.
- Preferred embodiments of the compound (I) include the compound (II).
- the compound (II) preferably the as A 1 (a 1), ( bl), (b 2), (c 1), (dl), (d 2), (el), (e 2), (Fl), (gl), (hi), or (i 1), more preferably (a 1) or (c 1), c is particularly preferably A 1 is (a 1) group R 1 is hydrogen, R 2 is halogen (e.g. F, C 1, etc.), lower alkyl (e.g. methyl, t one-butyl, etc.), lower alkoxy (e.g.
- R 3 is hydrogen, Nono androgenic (eg: F, C 1 or the like ), Lower alkyl (eg, methyl, t-butyl, etc.), lower alkoxy (eg, methoxy, ethoxy, etc.), or halogen Emissions lower alkyl: a (eg CF 3, etc.).
- R 3 is particularly preferably hydrogen. When R 2 and R 3 are halogen, the m- and p-positions are particularly preferred.
- B 1 is preferably a radical of (0), (ol) or (02).
- R 4 is preferably hydrogen
- R 5 is preferably hydrogen, halogen, amino, carboxyl, hydroxy, cyano, lower alkyl (eg, methyl, ethyl, isopropyl, t-butyl, etc.), optionally substituted lower alkoxy (eg main butoxy, carboxymethyl butoxy, main butoxycarbonyl main butoxy, etc.), lower alkoxy Cal Poni Le (eg main Tokishikaru Boniru etc.), halogenated lower alkyl (e.g. CF 3, etc.), Ariruokishi (e.g. Fueniruokishi etc.) Or heteroaryloxy (eg, 2-thiophenyloxy, 41-pyridyloxy, etc.).
- X 1 is preferably 0.
- X 2 is preferably an NH CO-, one NH CONH-, - NH S 0 2 -, or a group shown below:
- n is preferably 3.
- compound (II) is a group wherein A ⁇ is (al); R 1 is hydrogen; R 2 is halogen, lower alkyl, lower alkoxy, halogenated lower alkyl, or substituted phenyl. R 3 is hydrogen, halogen, lower alkyl, lower alkoxy, or lower alkyl halide; B 1 is a group of (0), (ol) or (o2); R 4 is hydrogen, R 5 is hydrogen, halogen, X 1 is 0; amino, carboxyl, hydroxy, cyano, lower alkyl, optionally substituted lower alkoxy, lower alkoxyl propyl, halogenated lower alkyl, aryloxy, or heteroaryloxy; X 2 is —NH CO—, —NH CONH—, —NH S 0 2 —, or (x-1), (x_2), (x_5), (x-6), (x-7) or (x -8) Group: m is 0 and n is 3. Among
- X 2 is - NR b S 0 2 -, -NR b CO-, or - NR b C 0 NR b -
- Y 1 represents a leaving group (eg a halogen such); Zeta is S 0 2, C0, C_ ⁇ _NR b; the other symbols are as defined above)
- compound (III) and compound (IV) are reacted in the presence of a base, if desired, to give compound (I).
- a base carbonates (K 2 C 0 3, Na 2 C0 3 , etc.) or Na OH, 3 tertiary Amin (Example: E t 3 N) can be used like. KI may be used in combination.
- the solvent CH 3 CN, dimethylformamide (DMF), dimethylsulfoxide (DMS 0), tetrahydrofuran (THF) and the like can be used.
- the reaction temperature is usually About 10 to 200 ° (: preferably room temperature to about 110 ° C, and the reaction time is several hours to several tens of hours, preferably about 1 to 20 hours, more preferably about 3 to 1 hour.
- the conjugate (III) and the compound (IV) may be synthesized by a well-known reaction or a commercially available product may be used.
- Compound (V) is reacted with compound (VI) in the presence of a base, if desired, to give compound (VII).
- a base carbonates (K 2 C_ ⁇ 3, Na 2 C0 3, etc.), Na OH, t- BuOK, 3 tertiary Amin (Example: E t 3 N) can be used like. KI may be used in combination.
- the solvent CH 2 C 1 2, CH 3 CN, dimethylformamidine de (DM F), dimethyl sulfoxide (DMS O), as tetrahydrofuran (THF) or the like can be used.
- the reaction temperature is usually from room temperature to about 100 ° C, preferably from room temperature to about 60 ° C, and the reaction time is from several hours to several tens hours, preferably from about 1 to 20 hours, more preferably about 3 to 20 hours. ⁇ 15 hours.
- Compound (V) and compound (VI) may be synthesized by a well-known reaction, or a commercially available product may be used.
- compound (VII) is oxidized to obtain compound (I).
- oxidizing agent m-chloroperbenzoic acid, hydrogen peroxide, peracid, potassium permanganate, periodic acid and the like can be used.
- solvent CH 2 C 1 2, CH 3 CN, dimethylformamidine de (DM F), dimethyl sulfoxide (DMS O), Te Jerusalemi Dorofuran (TH F) and the like Can be used.
- the reaction temperature is usually about 0-50, preferably about 0. (: To room temperature, and the reaction time is several hours to several tens of hours, preferably about 1 to 20 hours, more preferably about 3 to 15 hours.
- Z 1 is a single bond, 1 0—, — NR b CO—, — NR b S 0 2 —, and other symbols are as defined above
- the compound (V) and the compound (IX) are reacted in the presence of a base, if desired, to obtain a compound (I).
- a base carbonates (K 2 C0 3, Na 2 C0 3 , etc.) or NaOH, 3 amine or the like can be used. KI may be used in combination.
- the solvent CH 3 CN, dimethylformamide (DMF), dimethylsulfoxide (DMSO) and the like can be used.
- the reaction temperature is usually about 10 to 200 ° C, preferably room temperature to about 110 ° C, and the reaction time is several hours to several tens hours, preferably about 1 to 20 hours, and more preferably. Approximately 3 to 15 hours.
- Compound (IX) may be synthesized by a well-known reaction, or a commercially available product may be used.
- Compound (X) is reacted with compound (XI) in the presence of a base, if desired, to give compound (I).
- a base carbonates (K 2 C0 3, Na 2 C0 3 , etc.) and Na_ ⁇ H, 3 tertiary Amin (Example: E t 3 N) can be used like. KI may be used in combination.
- the solvent CH 3 CN, dimethylformamide (DMF), dimethylsulfoxide (DMSO), tetrahydrofuran (THF) and the like can be used.
- the reaction temperature is usually about 10 to 200 ° C, preferably room temperature to about 110 ° C, and the reaction time is several hours to several tens hours, preferably about 1 to 20 hours, more preferably About 3 to 15 hours.
- Compound (II) and compound (IV) may be synthesized by a well-known reaction, or a commercially available product may be used.
- an appropriate protection reaction may be carried out on the functional group according to a method well known to those skilled in the art, and a deprotection reaction may be carried out after the reaction.
- Examples of the pharmaceutically acceptable salt of compound (I) include salts formed with inorganic bases, ammonia, organic bases, inorganic acids, organic acids, basic amino acids, halogen ions and the like, or internal salts.
- Examples of the inorganic base include alkali metals (Na, K, etc.), alkaline earth metals (Ca, Mg, etc.), and examples of the organic bases include trimethylamine, triethylamine, choline, proline, ethanolamine, etc. Is done.
- Examples of the inorganic acid include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like.
- organic acid examples include p-toluenesulfonic acid, methanesulfonic acid, formic acid, trifluoroacetic acid, maleic acid, and oxalic acid.
- basic amino acid examples include lysine, argin, ordinine, histidine and the like.
- Compound (I) may be a solvate such as water or alcohol.
- a prodrug is a derivative of a compound of the present invention that has a chemically or metabolically degradable group and is a compound that becomes a pharmaceutically active compound of the present invention by solvolysis or under physiological conditions in vivo. Methods for selecting and producing suitable prodrug derivatives are described, for example, in Design of Prodrugs, E 1 sevier, Amsterdam. 1985.
- an ester derivative prepared by reacting an acidic compound with an appropriate alcohol or an ester derivative prepared by reacting an acidic compound with an appropriate amine.
- examples of such prodrugs include amide derivatives, such as methyl ester, ethyl ester, n-propyl ester, isopropyl ester, n-butyl ester, isobutyl ester, tert-butyl ester, and morpholinoethyl ester. .
- a prodrug such as an acyloxy derivative produced by reacting a compound having a hydroxyl group with a suitable acyl halide or a suitable acid anhydride is exemplified.
- a prodrug such as an acyloxy derivative produced by reacting a compound having a hydroxyl group with a suitable acyl halide or a suitable acid anhydride.
- prodrugs such as amide derivatives produced by reacting the compound having an amino group with a suitable acid halide or a suitable mixed acid anhydride are exemplified.
- a suitable acid halide or a suitable mixed acid anhydride
- one NH CO (CH 2 ) 2 . CH 3 one NH 2 CO CH (NH 2) CH 3 and the like.
- the compound (I), in particular, the compound (II) can be orally or parenterally administered to animals including humans as a medicament, particularly as a preventive or therapeutic agent for diabetes.
- dosage forms include granules, tablets, capsules, and injections.
- various additives such as excipients, disintegrants, binders, lubricants, stabilizers, coloring agents, and coating agents can be used as desired.
- the dosage varies depending on the subject's age, body weight, symptoms, administration method, etc., and is not particularly limited.However, it is usually about 20 mg to about 1000 mg per day for an adult, and about 20 mg to about 1000 mg for a parenteral administration. About 2 mg to about 100 mg.
- compound (I) increases glucose utilization and consequently lowers blood glucose.
- the mechanism of action includes (1) increased responsiveness to insulin in each organ (improved insulin resistance), (2) increased insulin secretion due to increased sensitivity to glucose in the rat, and (3) ) It is possible that insulin synthesis in the kidney may be accelerated. That is, compound (I) is useful as an agent for preventing or treating type I or type II diabetes, preferably type II diabetes.
- the organic layer is washed with water and saturated saline, and the organic layer is dried over MgSO, and the solvent is distilled off under reduced pressure.
- the organic layer is washed with water and saturated saline, and the organic layer is dried over MgSC ⁇ and the solvent is distilled off under reduced pressure.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020017014463A KR20020002501A (ko) | 1999-05-13 | 2000-05-10 | 당뇨병의 예방 또는 치료약 |
CA002372715A CA2372715A1 (en) | 1999-05-13 | 2000-05-10 | Preventive or therapeutic drugs for diabetes |
EP00927740A EP1190710A4 (en) | 1999-05-13 | 2000-05-10 | PREVENTIVE OR THERAPEUTIC MEDICATIONS FOR DIABETES |
AU46123/00A AU4612300A (en) | 1999-05-13 | 2000-05-10 | Preventive or therapeutic drugs for diabetes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/132375 | 1999-05-13 | ||
JP13237599 | 1999-05-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001024786A1 true WO2001024786A1 (fr) | 2001-04-12 |
Family
ID=15079914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/002992 WO2001024786A1 (fr) | 1999-05-13 | 2000-05-10 | Principes actifs destines au soin ou a la prevention de diabetes |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1190710A4 (ja) |
KR (1) | KR20020002501A (ja) |
CN (1) | CN1350452A (ja) |
AU (1) | AU4612300A (ja) |
CA (1) | CA2372715A1 (ja) |
WO (1) | WO2001024786A1 (ja) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003059870A1 (fr) * | 2002-01-17 | 2003-07-24 | Shionogi & Co., Ltd. | Derives sulfonamide n-substitues et medicaments preventifs ou therapeutiques pour soigner le diabete renfermant ces derives |
US7109203B2 (en) * | 2001-05-14 | 2006-09-19 | Novartis Ag | Sulfonamide derivatives |
JP2007515490A (ja) * | 2003-12-22 | 2007-06-14 | アムジェン インコーポレーティッド | アリールスルホンアミド化合物およびそれに関連する使用法 |
WO2008096189A2 (en) | 2005-09-23 | 2008-08-14 | M's Science Corporation | Piperidine and piperazine derivatives |
US7514457B2 (en) | 2005-05-31 | 2009-04-07 | Pfizer Inc. | Substituted aryloxymethyl bicyclicmethyl acetamide compounds |
JP2009524663A (ja) * | 2006-01-27 | 2009-07-02 | 株式会社エムズサイエンス | ピペリジン誘導体及びピペラジン誘導体 |
WO2009142571A1 (en) | 2008-05-20 | 2009-11-26 | Astrazeneca Ab | Phenyl and benzodioxinyl substituted indazoles derivatives |
US7728030B2 (en) | 2006-12-21 | 2010-06-01 | Astrazeneca Ab | Chemical compounds 572 |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
US8030340B2 (en) | 2006-11-23 | 2011-10-04 | Astrazeneca Ab | Indazolyl sulphonamide derivatives useful as glucocorticoid modulators |
WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
US8247442B2 (en) | 2006-03-29 | 2012-08-21 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use |
US8399486B2 (en) | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
US8765736B2 (en) | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
US8791264B2 (en) | 2006-04-13 | 2014-07-29 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
US8937181B2 (en) | 2006-04-13 | 2015-01-20 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
US9000174B2 (en) | 2004-10-14 | 2015-04-07 | Purdue Pharma L.P. | 4-phenylsulfonamidopiperidines as calcium channel blockers |
CN113373187A (zh) * | 2021-05-26 | 2021-09-10 | 江苏阿尔法药业股份有限公司 | 一种氮杂环化合物c27h30fno6的酶催化合成方法 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005035471A1 (ja) | 2003-10-14 | 2005-04-21 | Ajinomoto Co., Inc. | エーテル誘導体 |
CA2584413A1 (en) * | 2004-10-29 | 2006-05-04 | Astrazeneca Ab | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
EP2642998B1 (en) | 2010-11-24 | 2020-09-16 | The Trustees of Columbia University in the City of New York | A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease |
PL395470A1 (pl) | 2011-06-29 | 2013-01-07 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego |
US9333202B2 (en) | 2012-05-01 | 2016-05-10 | The Trustees Of Columbia University In The City Of New York | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease |
US9938291B2 (en) | 2013-03-14 | 2018-04-10 | The Trustess Of Columbia University In The City Of New York | N-alkyl-2-phenoxyethanamines, their preparation and use |
DK2968304T3 (en) | 2013-03-14 | 2019-01-28 | Univ Columbia | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE. |
EP2968303B1 (en) | 2013-03-14 | 2018-07-04 | The Trustees of Columbia University in the City of New York | Octahydrocyclopentapyrroles, their preparation and use |
US9944644B2 (en) | 2013-03-14 | 2018-04-17 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles their preparation and use |
ES2909793T3 (es) | 2014-04-30 | 2022-05-10 | Univ Columbia | 4-fenilpiperidinas sustituidas, su preparación y uso |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995025721A1 (de) * | 1994-03-24 | 1995-09-28 | Schering Aktiengesellschaft | Neue 1,4-disubstituierte piperidin-derivate als auf den glutamat-rezeptor wirkende arzneimittel |
JPH0892249A (ja) * | 1994-07-20 | 1996-04-09 | Sankyo Co Ltd | スルホンアミド誘導体 |
WO2000006558A1 (en) * | 1998-07-28 | 2000-02-10 | Merck Patent Gmbh | Antidiabetic piperazine derivatives, processes for their preparation and compositions containing them |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997028115A1 (en) * | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Antidiabetic agents |
US5847008A (en) * | 1996-02-02 | 1998-12-08 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
-
2000
- 2000-05-10 WO PCT/JP2000/002992 patent/WO2001024786A1/ja not_active Application Discontinuation
- 2000-05-10 EP EP00927740A patent/EP1190710A4/en not_active Withdrawn
- 2000-05-10 AU AU46123/00A patent/AU4612300A/en not_active Abandoned
- 2000-05-10 CA CA002372715A patent/CA2372715A1/en not_active Abandoned
- 2000-05-10 KR KR1020017014463A patent/KR20020002501A/ko not_active Application Discontinuation
- 2000-05-10 CN CN00807513A patent/CN1350452A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995025721A1 (de) * | 1994-03-24 | 1995-09-28 | Schering Aktiengesellschaft | Neue 1,4-disubstituierte piperidin-derivate als auf den glutamat-rezeptor wirkende arzneimittel |
JPH0892249A (ja) * | 1994-07-20 | 1996-04-09 | Sankyo Co Ltd | スルホンアミド誘導体 |
WO2000006558A1 (en) * | 1998-07-28 | 2000-02-10 | Merck Patent Gmbh | Antidiabetic piperazine derivatives, processes for their preparation and compositions containing them |
Non-Patent Citations (1)
Title |
---|
See also references of EP1190710A4 * |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7109203B2 (en) * | 2001-05-14 | 2006-09-19 | Novartis Ag | Sulfonamide derivatives |
WO2003059870A1 (fr) * | 2002-01-17 | 2003-07-24 | Shionogi & Co., Ltd. | Derives sulfonamide n-substitues et medicaments preventifs ou therapeutiques pour soigner le diabete renfermant ces derives |
JP2007515490A (ja) * | 2003-12-22 | 2007-06-14 | アムジェン インコーポレーティッド | アリールスルホンアミド化合物およびそれに関連する使用法 |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
US9000174B2 (en) | 2004-10-14 | 2015-04-07 | Purdue Pharma L.P. | 4-phenylsulfonamidopiperidines as calcium channel blockers |
US7514457B2 (en) | 2005-05-31 | 2009-04-07 | Pfizer Inc. | Substituted aryloxymethyl bicyclicmethyl acetamide compounds |
WO2008096189A2 (en) | 2005-09-23 | 2008-08-14 | M's Science Corporation | Piperidine and piperazine derivatives |
JP2009524663A (ja) * | 2006-01-27 | 2009-07-02 | 株式会社エムズサイエンス | ピペリジン誘導体及びピペラジン誘導体 |
EP2340835A1 (en) | 2006-01-27 | 2011-07-06 | M's Science Corporation | Piperidine and piperazine derivatives |
US8247442B2 (en) | 2006-03-29 | 2012-08-21 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use |
US8937181B2 (en) | 2006-04-13 | 2015-01-20 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
US8791264B2 (en) | 2006-04-13 | 2014-07-29 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
US8030340B2 (en) | 2006-11-23 | 2011-10-04 | Astrazeneca Ab | Indazolyl sulphonamide derivatives useful as glucocorticoid modulators |
US7728030B2 (en) | 2006-12-21 | 2010-06-01 | Astrazeneca Ab | Chemical compounds 572 |
US8143290B2 (en) | 2006-12-21 | 2012-03-27 | Astrazeneca Ab | Chemical compounds 572 |
US8399486B2 (en) | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
US8765736B2 (en) | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
WO2009142571A1 (en) | 2008-05-20 | 2009-11-26 | Astrazeneca Ab | Phenyl and benzodioxinyl substituted indazoles derivatives |
EP2620435A1 (en) | 2008-05-20 | 2013-07-31 | Astrazeneca AB | Phenyl and benzodioxinyl substituted indazole derivatives |
US9738632B2 (en) | 2008-05-20 | 2017-08-22 | Astrazeneca Ab | Phenyl and benzodioxinyl substituted indazoles derivatives |
US9512110B2 (en) | 2008-05-20 | 2016-12-06 | Astrazeneca Ab | Phenyl and benzodioxinyl substituted indazoles derivatives |
US8916600B2 (en) | 2008-05-20 | 2014-12-23 | Astrazeneca Ab | Phenyl and benzodioxinyl substituted indazoles derivatives |
US8211930B2 (en) | 2008-05-20 | 2012-07-03 | Astrazeneca Ab | Phenyl and benzodioxinyl substituted indazoles derivatives |
WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
EP3708179A1 (en) | 2012-03-15 | 2020-09-16 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
EP4309673A2 (en) | 2012-03-15 | 2024-01-24 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
EP4424697A2 (en) | 2013-06-05 | 2024-09-04 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
CN113373187A (zh) * | 2021-05-26 | 2021-09-10 | 江苏阿尔法药业股份有限公司 | 一种氮杂环化合物c27h30fno6的酶催化合成方法 |
CN113373187B (zh) * | 2021-05-26 | 2023-11-10 | 江苏阿尔法药业股份有限公司 | 一种氮杂环化合物c27h30fno6的酶催化合成方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1190710A4 (en) | 2003-04-02 |
EP1190710A1 (en) | 2002-03-27 |
CN1350452A (zh) | 2002-05-22 |
CA2372715A1 (en) | 2001-04-12 |
AU4612300A (en) | 2001-05-10 |
KR20020002501A (ko) | 2002-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001024786A1 (fr) | Principes actifs destines au soin ou a la prevention de diabetes | |
JP3866041B2 (ja) | スルホンアミド含有インドール化合物 | |
JP4482513B2 (ja) | N2−(置換アリールメチル)−3−(置換フェニル)インダゾールおよびこれを含む抗血管形成剤 | |
BR112012007828B1 (pt) | compostos inibidores da xantina oxidase, processo para preparar os compostos, e, composição farmacêutica para a inibição da xantina oxidase | |
PT1258484E (pt) | Novos compostos de isoxazol e de tiazol e sua utilização enquanto fármacos | |
BRPI0611853A2 (pt) | derivados de n-(piridin-2-il)-sulfonamida | |
WO1998018765A1 (fr) | Composes de 1-phenylpyrazole et leur application pharmaceutique | |
PT1442030E (pt) | Tiofenossulfonamidas e tiazolessulfonamidas como agentes antineoplásicos | |
CN106029072A (zh) | 杂环化合物和使用方法 | |
JP2005232179A (ja) | 3−フェニルスルホニル−3,7−ジアザビシクロ[3,3,1]ノナン−化合物を含有する抗不整脈剤 | |
BR112019020075A2 (pt) | composto, e, composição farmacêutica | |
WO2000039097A1 (fr) | Composes d'imidazole et utilisation medicinale de ces composes | |
JP2000514821A (ja) | ピラゾロピリジン化合物およびその医薬用途 | |
JP3040473B2 (ja) | 抗不整脈及び抗細動剤として有用な新規4−オキソ環式尿素類 | |
JPWO2003051854A1 (ja) | チアジアゾリン誘導体 | |
CA3104956A1 (en) | Novel lxr modulators with bicyclic core moiety | |
WO2006051312A1 (en) | Gastrin and cholecystokinin receptor ligands | |
WO2017198179A1 (zh) | 新型噻唑类衍生物在治疗炎性肠病中的应用 | |
WO1997026242A1 (fr) | Derives de 3-(bis-phenylmethylene substitue) oxindole | |
WO2003002540A1 (en) | Cyclic diamine compound having five-membered cyclic group | |
JPH0327382A (ja) | ジヒドロイミダゾキノリノンオキシムスルホン酸誘導体 | |
CN111138422B (zh) | 一种用于防治红斑狼疮的药物及其制备方法 | |
WO1994014769A1 (en) | N-substituted indole derivative | |
WO1998054131A1 (fr) | Nouveaux derives sulfonamides | |
JPH05201971A (ja) | 環状アミン含有ベンゼンスルホンアミド誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00807513.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2001 527785 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2372715 Country of ref document: CA Ref document number: 2372715 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09959760 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017014463 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000927740 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017014463 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2000927740 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000927740 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020017014463 Country of ref document: KR |